CLINICAL TRIALS PROFILE FOR EFFEXOR

505(b)(2) Clinical Trials for EFFEXOR

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT05875610 ↗	Preventive Approach Using Venlafaxine	Recruiting	Mit Ghamr Oncology Center	Phase 4	2023-05-01	Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients.

All Clinical Trials for EFFEXOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001483 ↗	Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression	Completed	National Institute of Mental Health (NIMH)	Phase 2	1995-06-01	This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway. Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI). Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor. Subjects enrolled in this study will be patients diagnosed with a bipolar disorder who are presently taking medication to prevent the symptoms of the disease (prophylactic treatment), but have had breakthrough episodes of depression despite taking their medication. Patients will receive any one of the three antidepressant medications as noted above plus a placebo inactive sugar pill, in order to mask which antidepressant is being prescribed) in addition to their regular medication for bipolar disorder. All of the doses will be calculated as effective for the treatment of a unipolar major depressive disorder. The patient will continue receiving the medication for ten weeks. The effectiveness of the drug treatment will be measured by using three different scales; 1. Inventory for Depressive Symptoms - Clinicians form (IDS-C) 2. Clinical Global Impression scale(CGI-BP) 3. Life Charting Methodology (LCM) Patients who do not respond to their medication within ten weeks from the beginning of the study will be considered as non-responders and be offered the opportunity to start the study again, taking one of the two remaining medications. For example, if a patient was assigned to take Wellbutrin but it was ineffective, he/she could re-enter the study and be given either Zoloft or Effexor. Patients that do respond in the first ten weeks of the study will be eligible to continue taking the medication for one year to assess the long term effectiveness of the drug on preventing episodes of depression and to assess for any possible differential induction of mania.
NCT00043550 ↗	Treatments for Depression: Drug Versus Psychotherapy	Completed	National Institute of Mental Health (NIMH)	Phase 3	2001-11-01	This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
NCT00043550 ↗	Treatments for Depression: Drug Versus Psychotherapy	Completed	University of Pennsylvania	Phase 3	2001-11-01	This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
NCT00045916 ↗	Optimizing Electroconvulsive Therapy for Depression	Completed	National Institute of Mental Health (NIMH)	Phase 4	2001-02-01	This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT.
NCT00045916 ↗	Optimizing Electroconvulsive Therapy for Depression	Completed	New York State Psychiatric Institute	Phase 4	2001-02-01	This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT.
NCT00046020 ↗	Study Evaluating Venlafaxine ER in Recurrent Depression	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 4	2000-08-01	The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
NCT00086190 ↗	Study of Antidepressants in Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 3	2005-06-01	The purpose of this study is to find out if two antidepressant medications, paroxetine and venlafaxine, can help control depression in Parkinson's disease, and if these medications affect the motor symptoms of Parkinson's disease such as tremor, stiffness, slowness, and balance.

Clinical Trial Conditions for EFFEXOR

Condition Name

Condition Name for EFFEXOR
Intervention	Trials
Depression	15
Healthy	12
Major Depressive Disorder	10
Depressive Disorder, Major	4

Condition MeSH

Condition MeSH for EFFEXOR
Intervention	Trials
Depression	33
Depressive Disorder	28
Depressive Disorder, Major	15
Disease	11

Clinical Trial Locations for EFFEXOR

Trials by Country

Trials by Country for EFFEXOR
Location	Trials
United States	115
Japan	47
Canada	12
China	12
United Kingdom	3

Trials by US State

Trials by US State for EFFEXOR
Location	Trials
New York	10
Florida	8
California	6
North Carolina	6
Missouri	6

Clinical Trial Progress for EFFEXOR

Clinical Trial Phase

Clinical Trial Phase for EFFEXOR
Clinical Trial Phase	Trials
Phase 4	23
Phase 3	9
Phase 2	6

Clinical Trial Status

Clinical Trial Status for EFFEXOR
Clinical Trial Phase	Trials
Completed	48
Unknown status	4
Withdrawn	4

Clinical Trial Sponsors for EFFEXOR

Sponsor Name

Sponsor Name for EFFEXOR
Sponsor	Trials
Wyeth is now a wholly owned subsidiary of Pfizer	7
Teva Pharmaceuticals USA	5
National Institute of Mental Health (NIMH)	5

Sponsor Type

Sponsor Type for EFFEXOR
Sponsor	Trials
Other	52
Industry	32
NIH	10

EFFEXOR Market Analysis and Financial Projection

Last updated: April 29, 2026

Effexor (venlafaxine): Clinical Trial Update, Market Analysis, and Projection

What is Effexor and what is its current clinical footprint?

Effexor is the brand name for venlafaxine, an SNRI antidepressant marketed in multiple formulations (notably immediate-release and extended-release). It is an established product with long-standing global use and a large legacy clinical record across major depressive disorder and related psychiatric indications.

Clinical trial update (high level):

• Effexor’s clinical development profile is mature, with the active pipeline focus shifting toward:
  • New formulations and controlled-release technologies rather than first-in-class reinvention.
  • Label expansions that consolidate existing evidence and support country-specific regulatory requirements.
  • Conduct studies for new competitors’ contexts, where endpoints, comparators, and statistical designs align with updated guideline expectations.

Trial registration and evidence base (what tends to remain active):

• Post-approval studies commonly include:
  • PK/PD and bioequivalence work across generics and branded formulations.
  • Safety surveillance and observational research.
  • Niche populations and real-world effectiveness cohorts.
• Large pivotal phase programs typical of novel CNS assets are generally not a dominant feature for established venlafaxine brands; the evidence is already built out through decades of controlled trials.

Core implication for investors and R&D planners:

• Effexor is not positioned like a late-stage pipeline asset; it functions like a mature branded platform in markets where generics exist and the question is pricing, share retention, and channel execution rather than fundamental efficacy differentiation.

What does the competitive landscape look like for Effexor?

Effexor competes primarily within antidepressant classes, where payers optimize for:

• Generic availability
• Place in therapy
• Formulary tiering
• Switchability and tolerability profiles

Competitive set (functional substitutes):

• Other SNRIs: duloxetine
• Other antidepressant classes: SSRIs (e.g., sertraline, escitalopram) and branded agents depending on geography
• Generic venlafaxine and authorized generics depending on market

Market structure impact:

• In most countries, venlafaxine has faced extensive generic substitution, compressing pricing and raising the importance of:
  • contract pricing and formulary access
  • stable supply and switching programs
  • brand differentiation through patient support and prescriber familiarity

---

Market Analysis

How big is the Effexor market and what drives revenue?

Because Effexor is an older, largely generic-exposed product globally, market value is driven more by share, geography, and pricing mechanics than by new clinical adoption from pivotal development.

Key revenue drivers:

• Generics penetration and whether the brand retains a significant premium
• Formulary positioning (preferred vs non-preferred SNRI/antidepressants)
• Switch rates driven by adverse-event patterns and payer policies
• Country-level pricing controls (tends to cap branded pricing)
• Contracting and tender dynamics in public payer systems
• Switchback dynamics: when payers change coverage rules, clinicians sometimes move patients back to previously effective agents.

Where brand tends to persist:

• Markets with slower substitution dynamics
• Systems with continuing branded use due to:
  • prescriber practice patterns
  • brand-specific packaging programs
  • patient tolerance history

Where brand tends to shrink:

• Markets with aggressive generic tender cycles
• Systems that push first-line SSRIs and reserve SNRIs for partial responders
• Places where formularies actively reduce SNRI brand premiums

What does demand look like by indication?

Effexor’s demand remains tied to:

• Major depressive disorder maintenance and relapse prevention
• Generalized anxiety disorder (in jurisdictions where approved)
• Social anxiety disorder (in jurisdictions where approved)
• Other labeled anxiety spectrum uses depending on local label

Demand is not typically driven by “new patient starts” in the way newer CNS drugs are; it is driven by:

• continuation therapy (relapse prevention)
• switching among SNRIs
• treatment after inadequate response to SSRIs

---

Projection Framework

What is the realistic 3- to 7-year outlook for Effexor revenue and volume?

For a mature antidepressant with extensive generic exposure, projection typically depends on three variables:

1. Pricing erosion (ongoing, unless defended through contracting in a subset of markets)
2. Share stability (brand persistence versus further generics capture)
3. Volume resilience (baseline market usage and continuity in treated populations)

Directional projection (industry-consistent for legacy CNS assets):

• Volume: relatively stable to modestly declining, supported by chronic relapsing nature of depression and switching patterns between antidepressants.
• Value: more likely to decline due to pricing pressure from generics and payer-driven tiering.
• Geographic variability: public payer countries can show sharper value compression; private markets can show more stable volume but still price down.

Scenario table (projection logic, not aspirational targets)

Horizon	Base case trend	Downside trend	Upside trend	Key sensitivities
12-24 months	modest volume stability; further price erosion	continued tender-driven pricing drops; faster brand share loss	slower substitution in key geographies; improved formulary retention	contract terms, tender cadence, payer policies
3-4 years	low single-digit value decline; flat-to-down volume	accelerated generic share capture	brand protected in select channels	share retention, switching programs
5-7 years	continued value contraction; volume gradual decline	stronger substitution; tighter SNRI restrictions	steady maintenance use and payer-neutral positioning	class preferences, guideline alignment

What would change the trajectory materially

• New regulatory expansions that create distinct clinical positioning (unlikely without new trials that meet modern endpoints for new populations)
• Patent or exclusivity restoration (not a general expectation for a legacy molecule like venlafaxine)
• Major distribution or contracting wins in large markets

---

Clinical Trials Update (How to interpret new filings for venlafaxine brand assets)

For legacy venlafaxine, “clinical trial activity” often does not mean new therapeutic breakthroughs. It usually indicates one of the following:

• bioequivalence / formulation comparisons
• dose or regimen optimization
• safety or tolerability evaluations
• real-world adherence and discontinuation patterns

Practical takeaways for R&D and investing:

• If a new trial shows up, it rarely implies a new mechanism or differentiated efficacy; it is more likely to affect:
  • packaging/formulation lifecycle
  • label maintenance
  • local regulatory compliance

---

Key Takeaways

• Effexor (venlafaxine) is a mature SNRI with an extensive legacy evidence base; clinical trial activity typically reflects formulation, PK, safety, and post-approval studies rather than pivotal novelty.
• Market performance depends mainly on generic penetration, payer formulary placement, and contracting dynamics, not on breakthrough clinical adoption.
• Projections for the next 3 to 7 years are most consistent with value erosion and relative volume resilience, with outcomes driven by country-level tender and tiering behavior.
• Material upside requires formulary or contract protection in large channels, not new clinical differentiation.

---

FAQs

1) Is Effexor still generating new clinical evidence?
Yes, but for legacy venlafaxine the majority of ongoing work is usually post-approval: formulation, bioequivalence, safety, and real-world studies rather than new phase-defining efficacy trials.

2) What most influences Effexor revenue in generics-heavy markets?
Pricing and formulary tiering. Brand share retention is usually tied to contracting and payer policy, not new mechanism-based differentiation.

3) What drives patient continuity on venlafaxine?
Depression relapse risk and tolerability history. Patients who respond and remain stable on an SNRI tend to continue unless payer coverage forces a switch.

4) Does the competition come from the same class?
Mostly yes, with SNRIs and SSRIs substituting through payer step therapy and prescriber switching practices.

5) What is the most realistic projection profile for a legacy antidepressant?
Stable to modestly declining volume with continued value erosion due to generic substitution and tiered pricing.

---

References

[1] FDA. Drug Trials Snapshots: Effexor XR (venlafaxine extended-release). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-trials-snapshots
[2] DailyMed. Effexor XR (venlafaxine hydrochloride) prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
[3] EMA. Assessment history and product information for venlafaxine-containing medicinal products. European Medicines Agency. https://www.ema.europa.eu/
[4] ClinicalTrials.gov. Search results for venlafaxine and venlafaxine hydrochloride (including formulation-related studies). U.S. National Library of Medicine. https://clinicaltrials.gov/